ArticleNucleic acids research2026
Staufen dsRNA-binding domain as modules to design bifunctional antibodies for siRNA delivery.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Antibody-small interfering RNA (siRNA) conjugates present an opportunity to expand the siRNA therapy to extrahepatic tissues. However, their investigation is now only confined to a limited number of targets, partially owing to some flaws in structures. Here, we described a modular design of bifunctional antibody that tethers siRNA without conjugation, yielding a diligent one-to-one antibody-siRNA pairing structure feasible for target expansion, charge masking, and further functionalization. Focusing on a noncationic siRNA-recruiting module, Staufen1 dsRBD34, we demonstrated that bifunctional antibodies recruit siRNA independent of base modification and enable target gene silencing on multiple cell types at a stoichiometry (1/1). Notably, by functionalizing siRNA terminus with small-molecule enhancers, the silencing potency of this pairing system can be augmented by seven times (IC50 from 200 to 28 nM) through the endosome-to-cytosol import. Affinity maturation by arginine scanning yields the 32 times higher affinity of dsRBD34 to siRNA, but the augment led to neither stronger silencing nor higher stability in mouse plasma as compared to p19 protein. The competition from sulfated GAGs in circulations can alter the pharmacokinetics of pairs and prevent a practical assessment of their potential in vivo. Altogether, bifunctional antibodies here possess notable properties, but ultrahigh-affinity dsRNA-binding domain is necessary to realize applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.